New meningococcal vaccine B arrives in Brazil
Vaccine against meningococcal B, a bacterium that causes not only meningitis but also other more serious diseases, has been launched in Brazil. The vaccine should be available by the end of May, first in private clinics. However, the intention is also to enter the official schedule of immunizations.
According to the infectious disease Juarez Cunha, of the Pediatric Society of Rio Grande do Sul, it is necessary to include new vaccines in the children's calendar. "Once the vaccines are included in the calendar, you can quickly see success when, for example, numbers fall," he says.
When the prevention of a serotype is lacking, it becomes more evident, increasing the incidence of this disease. In this way, including the vaccine in the calendar is a hope for the reduction in cases of type B meningitis. Initial laboratory-based studies indicate an effectiveness around 85%, which means an important coverage.
Your introduction will happen first in the private network for individual protection. In infants up to 1 year, the application schedule will be in 3 doses (2, 4 and 6 months), with reinforcement after completing the first year of life. For individuals between 1 and 50 years of age, two doses are indicated, with a two-month interval, with no need for reinforcement. Today, three different immunizations for meningococcal are being done, two to two months after the baby's life and another to three months.
Doctor Juarez Cunha emphasizes the importance of including the new vaccine in the official calendar for adolescents as well. "The recommendation is also to be made at age 19, as adolescents spend more time indoors, which facilitates the transmission of the bacteria that causes the disease," he says. However, the exact age indication for taking the vaccine in adolescence has not yet been confirmed.
Circulation . For more than 11 years, scholars have followed a group of 52,610 men and women. Each individual responded to questionnaires reporting the difficulty of falling asleep, the frequency they woke up and could not get back to sleep, and the number of times they awoke with the feeling of sleeping poorly, among other approaches.
Accordingly, scientists believe HAGE provides the basis for the creation of a therapeutic vaccine for cancer. triple-negative breast cancer and the development of a combined treatment between chemotherapy and the vaccine, aiming for better results. According to the researchers, in addition to the urgent need for a more individualized treatment for patients with triple negative type of breast cancer, the immunogenic potential of HAGE and its great protein expression in tumors, compared to healthy tissues, is what can make this type of cancer the best option for the vaccine.